News Content
Currently, once-weekly subcutaneous injection remains the globally recognized first-line dosage form. Its advantages include a bioavailability of over 95%, precise control of blood drug concentration, clear blood sugar-lowering and weight-loss effects, and a low incidence of adverse reactions. This dosage form has been approved in many countries for the treatment of type 2 diabetes and obesity management, with abundant clinical data accumulation and fully validated safety and efficacy, making it the first-line choice recommended by current medical guidelines.https://www.fiercerawsource.com/peptides/premium-high-purity-peptides-semaglutide.html
The emergence of oral dosage forms has addressed some patients' aversion to injections. Since its approval for oral semaglutide in 2021, it has quickly gained attention due to its convenience. However, its bioavailability is only 1/30th that of the injectable form due to gastrointestinal absorption limitations, requiring higher doses to achieve the same effect and potentially increasing the risk of gastrointestinal discomfort. It is more suitable for patients with mild diabetes or those with lower weight management needs.
Furthermore, the development of a long-acting sustained-release formulation has entered clinical trials. This formulation, using microsphere technology, allows for monthly or even quarterly dosing, further improving medication adherence, especially suitable for elderly patients or those requiring long-term medication. However, its development costs are high, and large-scale production has not yet been achieved; price and accessibility remain unresolved challenges.
In summary, injectable formulations remain the "best" due to their stable efficacy and high cost-effectiveness, oral formulations excel in convenience, and long-acting formulations represent the future direction. Patients should choose the most suitable formulation under the guidance of a doctor, considering their individual needs, the severity of their condition, and their financial situation. With the iteration of pharmaceutical technology, formulation innovation for semaglutide will continue, bringing more possibilities to chronic disease management.
